PAVmed Subsidiary Veris Health Partners with The Ohio State University Comprehensive Cancer Center for Pilot Program

In a significant development for PAVmed Inc. PAVM, a New York-based prominent medical device company, its subsidiary Veris Health has entered a Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James). The collaboration is set to implement a pilot program for the groundbreaking Veris Cancer Care Platform. This news has sparked interest within the healthcare community and among investors tracking developments in medical technology.

Pilot Program to Advance Cancer Care

The pilot program is designed to leverage the capabilities of the Veris Cancer Care Platform, aiming to transform the way cancer care is delivered. By integrating advanced technology and real-time health monitoring, the platform provides a proactive approach to managing patient care. The partnership with OSUCCC - James signifies an important step in bringing innovative solutions to the forefront of cancer treatment and underscores PAVmed's commitment to enhancing patient outcomes through cutting-edge technology.

Strategic Significance for PAVmed

This collaboration is not just a milestone for Veris Health, but also a strategic move for PAVmed Inc. PAVM, signaling its expanding presence in the healthcare solutions market. The pilot program with a leading cancer research and treatment facility like OSUCCC - James potentially paves the way for broader adoption of the Veris Cancer Care Platform, potentially impacting PAVmed's market position and investor interest.

pilot, partnership, innovation